title: Palmar-plantar erythrodysesthesia syndrome associated with liposomal daunorubicin.
abstract: Daunorubicin and doxorubicin are anthracyclines that have efficacy against malignancies such as breast cancer, lung cancer, lymphoma, and leukemia. Their adverse effects are similar. The most serious is cardiotoxicity, which often limits the total cumulative dose that can be administered. Introduction of a liposomal formulation for both agents allows tumor selectivity by accumulating the drug in tumor tissue, thus increasing the tolerated dose. Liposomal doxorubicin is commonly associated with palmar-plantar erythrodysesthesia syndrome (PPES), although no reports of PPES were found in the literature related to liposomal daunorubicin (L-DNR). Two patients developed PPES while receiving high-dose L-DNR. The symptoms were self-limiting and resolved within a few weeks.
authors.affiliation: Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston 77030, USA.
authors.forename: Y F
authors.initials: YF
authors.lastname: Hui
authors.forename: J E
authors.initials: JE
authors.lastname: Cortes
mesh_terms: D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage* / Q000009:adverse effects*; D003630:Daunorubicin / Q000008:administration & dosage* / Q000009:adverse effects*; D004334:Drug Administration Schedule; D004890:Erythema / Q000139:chemically induced*; D005260:Female; D005528:Foot; D006225:Hand; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008081:Liposomes; D008297:Male; D008875:Middle Aged; D010292:Paresthesia / Q000139:chemically induced*; D016879:Salvage Therapy
chemical_list: D000903:Antibiotics, Antineoplastic; D008081:Liposomes; D003630:Daunorubicin